Publicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (30)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

  5. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

    Journal of Hepatology

2023

  1. Long non-coding RNAs: definitions, functions, challenges and recommendations

    Nature Reviews Molecular Cell Biology, Vol. 24, Núm. 6, pp. 430-447

2022

  1. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  2. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 11, pp. 491.e11-491.e19

  3. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

  4. Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies

    Gut, Vol. 71, Núm. 6, pp. 1095-1105

  5. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83

2021

  1. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC

    Hepatology Communications, Vol. 5, Núm. 3, pp. 538-547

  2. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

  3. Elevated NSD3 histone methylation activity drives squamous cell lung cancer

    Nature, Vol. 590, Núm. 7846, pp. 504-508

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  5. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Leukemia, Vol. 35, Núm. 6, pp. 1722-1731

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

2019

  1. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets

    Journal of Hepatology, Vol. 71, Núm. 1, pp. 78-90

  2. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial

    JAMA Psychiatry, Vol. 76, Núm. 9, pp. 893-903

2018

  1. Basic and Translational Advances in Glioblastoma

    BioMed Research International